UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION IV
611 RYAN PLAZA DRIVE, SUITE 400
ARLINGTON, TEXAS 76011-4005

June 23, 2006

St. Alphonsus Regional Medical Center
ATTN: Timothy B. Stack, M.S.
Radiation Safety Officer
1055 North Curtis Road
Boise, Idaho 83706

SUBJECT: LICENSE AMENDMENT

Please find enclosed Amendment No. 28 to License No. 11-27306-01, **authorizing under license condition 16.F. the addition of a new location of use in the 5th floor of the North Tower of St. Alphonsus Regional Medical Center for nuclear medicine and brachytherapy procedures as requested.** An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14)(iv). You should review this license carefully and be sure that you understand all conditions. If you have any questions, you may contact me at 817-860-8189.

NRC's Regulatory Issue Summary (RIS) 2005-31, provides criteria to identify security-related sensitive information and guidance for handling and marking such documents. This ensures that potentially sensitive information is not made publicly available through NRC's electronic document system (ADAMS). The RIS may be located on the NRC Web site at: http://www.nrc.gov/reading-rm/doc-collections/gen-comm/reg-issues/2005/ and the link for frequently asked questions may be located at: http://www.nrc.gov/reading-rm/sensitive-info/faq.html. Pursuant to NRC's RIS 2005-31, this letter and its accompanying materials license will be made publicly available.

NRC expects licensees to conduct their programs with meticulous attention to detail and a high standard of compliance. Because of the serious consequences to employees and the public that can result from failure to comply with NRC requirements, you must conduct your radiation safety program according to the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate by NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers: Inspection and Investigations," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.

2. Notify NRC in writing of any change in mailing address.

3. By 10 CFR 30.36(d) and/or license condition, notify NRC, promptly, in writing, and request termination of the license:

   a. When you decide to terminate all activities involving materials authorized under the license whether at the entire site or any separate building or outdoor area; or

   b. If you decide not to acquire or possess and use authorized material; or

   c. When no principal activities under the license have been conducted for a period of 24 months.

4. In accordance with 10 CFR 35.14, notify the NRC no later than 30 days after:

   a. The date that the licensee permits an individual to work as an authorized user, an authorized nuclear pharmacist or an authorized medical physicist under 10 CFR 35.13(b)(1) through (b)(4);

   b. An authorized user, an authorized nuclear pharmacist, a Radiation Safety Officer, or an authorized medical physicist permanently discontinues duties under the license or has a name change;

   c. The licensee's mailing address changes;

   d. The licensee's name changes, but the name change does not constitute a transfer of control of the license as described in 10 CFR 30.34(b); or

   e. The licensee has added to or changed the areas of use identified in the application or on the license where byproduct material is used in accordance with either 35.100 or 35.200.

5. Request and obtain a license amendment before you:

   a. Change Radiation Safety Officers;

   b. Order byproduct material in excess of the amount, radionuclide or form authorized on the license;

   c. Add or change the areas or address(es) of use identified in the license application or on the license, except for areas of use where byproduct material is used only in accordance with either 10 CFR 35.100 or 35.200; or

   d. Change the name or ownership of your organization.

6. Submit a complete renewal application or termination request at least 30 days before the expiration date on your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of radioactive material after your license expires is a violation of NRC regulations.

NRC will periodically inspect your radiation safety program. Failure to conduct your program according to NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC may result in enforcement action against you. This could include issuance of a notice of violation; imposition of a civil penalty; or an order suspending, modifying, or revoking your license as specified in the NRC Enforcement Policy.

The NRC no longer publishes the NRC Rules and Regulations loose leaf supplements due to budget constraints. However, an electronic version of the NRC's regulations is available on the NRC Web site at www.nrc.gov. To view these regulations, highlight "Electronic Reading Room" and choose "Regulations" on the drop down menu. An electronic version of the NUREG-1556 Series publications is also available on the NRC Web site. To view these guidance documents, highlight "Electronic Reading Room"; choose "All Document Types" on the drop down menu; scroll down to "NUREG-Series Publications"; and select "Publications Prepared by the NRC Staff". Then, choose "NUREG-1556" from the table and select the appropriate volume(s) for your license type.

In accordance with 10 CFR 2.390 of the NRC's "Rules of Practice," a copy of this letter and its enclosure will be available electronically for public inspection in the NRC Public Document Room or from the NRC's document system (ADAMS). ADAMS is accessible from the NRC Web site at http://www.nrc.gov/reading-rm/adams.html.

Thank you for your cooperation.

Sincerely,

/RA/

Roberto J. Torres, Senior Health Physicist
Nuclear Materials Licensing Branch

Docket: 030-32263
License: 11-27306-01
Control: 470958

Enclosure: As stated

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated April 11, 2006
1. St. Alphonsus Regional Medical Center	3. License number 11-27306-01 is amended in its entirety to read as follows:
2. 1055 North Curtis Road Boise, Idaho 83706	4. Expiration date February 28, 2013
	5. Docket No. 030-32263 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted in 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted in 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted in 10 CFR 35.300	C. Any	C. 1,000 millicuries
D. Byproduct material listed below permitted by 10 CFR 35.400:	D. Brachytherapy sealed source Models listed below:	D. 1,500 millicuries total:
1. Cesium-137	1. Amersham Model CDC.T1	1. 80 millicuries per source
2. Iridium-192	2. Best Medical International, Inc. Model 81-01	2. 100 millicuries per source
3. Iodine-125	3. Amersham Model 6711	3. 270 millicuries per source
4. Iodine-125	4. Best Medical International, Inc. Model 2300 series	4. 110 millicuries per source
5. Iodine-125	5. Bebig Model 125.S06	5. 40 millicuries per source
6. Iodine-125	6. IsoStar Texas, Inc. Model IS-125 series	6. 10 millicuries per source
7. Iodine-125	7. North American Scientific Inc. Model MED 3631	7. 25 millicuries per source

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
11-27306-01

Docket or Reference Number
030-32263

Amendment No. 28

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
8. Iodine-125	8. Syncor Model BT-125-I	8. 6 millicuries per source
9. Iodine-125	9. International Brachytherapy Model 1251L	9. 5 millicuries per source
10. Palladium-103	10. Best Medical International, Inc. Model 2300 series	10. 110 millicuries per source
11. Palladium-103	11. North American Scientific Inc. Model MED 3633	11. 25 millicuries per source
12. Palladium-103	12. International Brachytherapy Model 1031L	12. 5 millicuries per source
13. Palladium-103	13. Theragenics Model 200	13. 10 millicuries per source
E. Strontium-90 permitted by 10 CFR 35.1000	E. Sealed sources (BEBIG Model Sr0.S03, AEAT SICW.2)	E. 5 millicuries per source; 800 millicuries total
F. Phosphorus-32 permitted by 10 CFR 35.1000	F. Sealed sources (Guidant Model GDT P-32 Series)	F. 600 millicuries per source assembly; 2 source assemblies total
G. Gadolinium-153	G. Sealed sources (NAS, Model 3601; Du Pont Merck, Model NES-8412; and IPL, Model A3410)	G. 300 millicuries per housing, total possession 2 curies
H. Iodine-125 permitted by 10 CFR 35.1000	H. Liquid as Proxima Therapeutics, Inc. Iotrex™	H. 8 curies

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B. Any imaging and localization study permitted by 10 CFR 35.200.
C. Any use permitted by 10 CFR 35.300.
D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
E. One source assembly for medical use in each Novoste A1000 Series model for intravascular brachytherapy permitted by 10 CFR 35.1000.
F. For use in the Guidant Corporation VI Model Galileo intravascular brachytherapy high dose rate afterloader devices for intravascular brachytherapy permitted by 10 CFR 35.1000.
G. For use in ADAC Laboratories Vantage transmission line source housings.
H. For brachytherapy use in the Proxima Therapeutics' GliaSite® Radiation Therapy System permitted by 10 CFR 35.1000.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
11-27306-01

Docket or Reference Number
030-32263

Amendment No. 28

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 1055 North Curtis Road, Boise, Idaho, and 10 CFR 35.65 material may also be used or stored in the PET scanner coach at 2929 East Magic View, Meridian, Idaho.

11. The Radiation Safety Officer for this license is Timothy B. Stack, M.S.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use:

Authorized Users	Material and Use
Ian Davey, M.D.	35.100; 35.200; 35.300; Gadolinium-153 for patient attenuation correction
Jeffrey T. Hall, M.D.	35.100; 35.200; Gadolinium-153 for patient attenuation correction
John Q. Knochel, M.D.	35.100; 35.200; 35.300; Gadolinium-153 for patient attenuation correction
William Murray, M.D.	35.100; 35.200; Gadolinium-153 for patient attenuation correction
Michael J. Ryan, M.D.	35.100; 35.200; oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries only for imaging and localization studies; Gadolinium-153 for patient attenuation correction
Paul Traughber, M.D.	35.100; 35.200; 35.300; Gadolinium-153 for patient attenuation correction
Curtis Coulam, M.D.	35.100; 35.200; 35.300; Gadolinium-153 for patient attenuation correction
Carolyn Ely Coffman, M.D.	35.100; 35.200; Gadolinium-153 for patient attenuation correction
David Koeplin, M.D.	35.300; 35.400; Strontium-90 and Phosphorus-32 for intravascular brachytherapy procedures; and Iodine-125 Iotrex™ in Proxima Therapeutics' GliaSite® Radiation Therapy System

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
11-27306-01

Docket or Reference Number
030-32263

Amendment No. 28

Authorized Users	Material and Use
Jeffrey Seabourn, M.D.	35.100; 35.200; 35.300; Gadolinium-153 for patient attenuation correction
Reginald Joseph Gobel, M.D.	35.100; 35.200; 35.300; Gadolinium-153 for patient attenuation correction
Vicken Garabedian M.D.	35.100; 35.200; Gadolinium-153 for patient attenuation correction
Neil Couchman Davey, M.D.	35.100; 35.200; Gadolinium-153 for patient attenuation correction
Lisa M. Scales, M.D.	35.100; 35.200; 35.300; Gadolinium-153 for patient attenuation correction
Timothy E. Sawyer, M.D.	35.300; 35.400; Strontium-90 and Phosphorus-32 for intravascular brachytherapy procedures; and Iodine-125 Iotrex™ in Proxima Therapeutics' GliaSite® Radiation Therapy System
Dallas D. Peck, M.D.	35.100; 35.200; Gadolinium-153 for patient attenuation correction
Jason Patrick Salber, M.D.	35.100; 35.200; 35.300
Bertram Jason Stemmler, M.D.	35.100; 35.200; oral administration of sodium iodide I-131
Howard B. Schaff, M.D.	35.100; 35.200; 35.300; Gadolinium-153 for patient attenuation correction
John A. Jackson, M.D.	35.100; 35.200; 35.300
William L. Taylor, M.D.	35.100; 35.200; oral administration of sodium iodide I-131
Anthony P. Giauque, M.D.	35.100; 35.200; 35.300

C. The following individual is an authorized medical physicist:

Authorized Medical Physicist	Material and Use
Timothy B. Stack, M.S.	Licensed material identified in Items 7.D. - 7.F. for calibration and training; and Iodine-125 Iotrex™ for activity calculation in association with the Proxima Therapeutics' GliaSite® Radiation Therapy System

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
11-27306-01

Docket or Reference Number
030-32263

Amendment No. 28

D. Intravascular brachytherapy procedures shall be conducted under the supervision of the authorized user, who will consult with the interventional cardiologist/physician and authorized medical physicist prior to initiating treatment. The procedures shall be conducted in the physical presence of the authorized user or the authorized medical physicist.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. The intravascular brachytherapy afterloader device shall be inspected and serviced at intervals recommended by the manufacturer, and maintenance and repair shall be performed only by the manufacturer or persons specifically licensed by NRC or an Agreement State to perform such services.

15. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated January 21, 2003
B. Letter dated February 18, 2003
C. Letter dated October 06, 2003
D. Letter dated October 27, 2003
E. Letter dated March 7, 2005
F. Letter dated April 11, 2006 (ML061360449)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

/RA/

Date: June 23, 2006

By: _____

Roberto J. Torres, Senior Health Physicist
Nuclear Materials Licensing Branch
Region IV
Arlington, Texas 76011